Skip to content

Two Out of Three Ain’t Bad

  • Chad Cipiti

In early August, FDA announced approvals of two fixed-dose combination (FDC) antiretroviral drug products for use with other antiretroviral agents in the treatment of HIV-1 infection: GlaxoSmithKline's Epzicom® (abacavir/lamivudine) and Gilead Sciences, Inc.'s Truvada® (tenofovir disoproxil/emtricitabine).

Read more

NIH Hearing on Norvir 400% Price Increase, 2004

  • Chad Cipiti

By Rob Camp Edited by Jen Curry AIDS Treatment Activists Coalition (ATAC) On Tuesday, May 25, 2004, the National Institutes of Health (NIH) hosted a public meeting to seek comment from invited individuals, organizations, and other stakeholders on the use…

Read more

2004 Pipeline Report

  • Chad Cipiti

February 2004 By Rob Camp Not so fast! Where's my pipeline? Pipelines are almost as delicate and fragile as the ecosystems they go trampling through. Oft times the way to get from the beginning to the end is not a…

Read more

TAG Postition Paper on Fosamprenavir Approval

  • Chad Cipiti

And speaking of boosting… By Rob Camp and Heidi Nass December 2003 Executive Summary FDA granted accelerated approval to Agenerase® brand amprenavir (NDA 21-007 and NDA 21-039) in April 1999. 908 allows us an opportunity to get an easier-to-use drug…

Read more

2003 Pipeline Report

  • Chad Cipiti

By Rob Camp The pipeline is bursting, with at least the following compounds twinkling in the eyes of scientists around the globe. It is by no means a full list, but those substances in red were presented at the recent…

Read more

Postition Paper on FDA Approval of Atazanavir (Reyataz)

  • Chad Cipiti

June 2003 By Rob Camp To lipid it or not to lipid it From the Introduction Atazanavir (ATV) is an azapeptide protease inhibitor under development by Bristol- Myers Squibb, licensed from Novartis. Overall, the drug looks virologically similar to nelfinavir…

Read more
Back To Top